THE WOODLANDS, Texas,
June 18, 2013 /PRNewswire/
-- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a
biopharmaceutical company focused on discovering breakthrough
treatments for human disease, announced today that John Northcott has joined the company as its
vice president of marketing, commercial strategy, and operations.
Mr. Northcott brings extensive commercial experience to Lexicon,
including both pre-launch planning and on-market commercialization
across a variety of therapeutic areas.
Mr. Northcott has held commercial roles in both U.S. and Global
marketing for Avastin® with Genentech and the Roche Group, having
most recently served as International Business Leader for Avastin,
leading global product strategy initiatives in oncology. In
addition, Mr. Northcott has experience in a variety of
therapeutic areas from previous commercial positions at other
pharmaceutical companies including Merck and Pfizer.
In this new position, Mr. Northcott will develop the commercial
functions for Lexicon and lead the commercialization of Lexicon's
products, with initial focus on telotristat etiprate for carcinoid
syndrome. The creation of the position reflects the progress of the
company's drug development pipeline and is part of its plan to
commercialize one or more drugs in specialty indications. Lexicon
is progressing with enrollment in the pivotal Phase 3 trial of
telotristat etiprate in carcinoid syndrome, which has Orphan and
Fast Track status from the FDA as well as Orphan status in
Europe. In addition, Lexicon is
proceeding with preparations for the initiation of Phase 3 clinical
trials of LX4211 in type 2 diabetes and is completing the Phase 2
program of LX1033 in irritable bowel syndrome.
"John is a talented commercial leader with extensive,
highly-relevant experience," said Dr. Arthur T. Sands, president and chief executive
officer of Lexicon. "He will be instrumental in formulating and
executing the strategic and operational plans essential to bring
Lexicon's innovative products to patients."
About Lexicon
Lexicon is a biopharmaceutical company
focused on discovering breakthrough treatments for human
disease. Lexicon currently has multiple programs in clinical
development for diabetes, irritable bowel syndrome, carcinoid
syndrome and other indications, all of which were discovered by
Lexicon's research team. Lexicon has used its proprietary
gene knockout technology to identify more than 100 promising drug
targets. Lexicon has focused drug discovery efforts on these
biologically-validated targets to create its extensive pipeline of
clinical and preclinical programs. For additional information
about Lexicon and its programs, please visit www.lexpharma.com.
Safe Harbor Statement
This press release contains "forward-looking statements,"
including statements relating to Lexicon's growth and
future operating results, discovery and development of products,
strategic alliances and intellectual property, as well as other
matters that are not historical facts or information. All
forward-looking statements are based on management's current
assumptions and expectations and involve risks, uncertainties and
other important factors, specifically including those relating to
Lexicon's ability to successfully conduct preclinical and clinical
development of its potential drug candidates, advance additional
candidates into preclinical and clinical development, obtain
necessary regulatory approvals, achieve its operational objectives,
obtain patent protection for its discoveries and establish
strategic alliances, as well as additional factors relating to
manufacturing, intellectual property rights, and the therapeutic or
commercial value of its drug candidates, that may cause Lexicon's
actual results to be materially different from any future results
expressed or implied by such forward-looking statements.
Information identifying such important factors is contained under
"Risk Factors" in Lexicon's annual report on Form 10-K for the year
ended December 31, 2012, as filed
with the Securities and Exchange Commission. Lexicon
undertakes no obligation to update or revise any such
forward-looking statements, whether as a result of new information,
future events or otherwise.
SOURCE Lexicon Pharmaceuticals, Inc.